US Pharma MarketingAfter withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings.
Odyssey, on second try, snags $279M in an IPO
After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings.
Source: BioPharma Dive